French biotech company Deinove has appointed Alexis Rideau as Deputy CEO, effective May 1, 2020.
Prior to joining Deinove, Alexis Rideau was in charge of developing industrial relations and coordinating the strategic partnership team at Bioaster, a Technology Research Institute in applied microbiology, which specializes in the design and use of technology innovations in the field of microbiology to accelerate the development of medical and nutritional industrial solutions for animal and human health.
Alexis Rideau has been directly involved in the definition and implementation of the Institute’s technology and economic strategy, as well as the valorization of its state-of-the-art technology platforms in the industrial sectors of microbiota, antimicrobials, vaccines and diagnostic. He initiated and implemented structuring partnerships, technologically and financially, with major French and international players (Takeda Pharmaceuticals, Bio-Rad Laboratories, bioMérieux, Boehringer Ingelheim, etc.), SMEs (Kaleido Biosciences Inc., Enterome, MaaT Pharma, LNC Therapeutics, Biofilm Pharma, etc.) and academic institutions (INRAE MetaGenoPolis, Institut Pasteur, CNRS, etc.).
Previously, Alexis Rideau held various positions in companies operating in the technology and healthcare fields, including support to entrepreneurs, sector analysis and fundraising (Library House Ltd, Bionest Partners and Glaizer Group) and directly in the field, in the conquest of new industrial markets (MorphoSys AG, Bio-Rad Laboratories).
Alexis Rideau holds a PhD in Molecular and Cellular Biology (University of Cambridge, England), a European Magistère in Genetics and an MSc in Cellular and Molecular Genetics (Paris Diderot University and Sorbonne University), as well as an MBA in International Management (ESCP Europe).
Deinove uses a disruptive approach, mainly based on an extensive screening program of its bacterial collection, to develop innovative antibiotics and bio-based active ingredients for cosmetic products, in particular skincare products.